Emend and Tecentriq drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Emend (aprepitant) and Tecentriq (atezolizumab). Common drug interactions include arthralgia among females and neuropathy peripheral among males.

The phase IV clinical study analyzes what interactions people have when they take Emend and Tecentriq. It is created by eHealthMe based on reports of 39 people who take the same drugs from the FDA, and is updated regularly.

What is Emend?

Emend has active ingredients of aprepitant. It is often used in nausea. eHealthMe is studying from 13,741 Emend users. Check the latest studies of Emend.

What is Tecentriq?

Tecentriq has active ingredients of atezolizumab. eHealthMe is studying from 12,796 Tecentriq users. Check the latest studies of Tecentriq.

On Jul, 16, 2026

39 people who take Emend and Tecentriq together, and have interactions are studied.

What are the common drug interactions of Emend and Tecentriq, by gender? *:

female:

Arthralgia (joint pain)
Pyrexia (fever)
Thyroid disorder (thyroid diseases)
Febrile neutropenia (fever with reduced white blood cells)
Death
Skin disorder (skin disease)

male:

Neuropathy peripheral (surface nerve damage)
Febrile neutropenia (fever with reduced white blood cells)
Gastric hypomotility (less movement of stomach)
Renal impairment (severely reduced kidney function)
Duodenal ulcer haemorrhage (bleeding duodenal ulcer)
Duodenitis haemorrhagic (inflammation of the duodenum with bleeding disorder)
Epistaxis (bleed from the nose)
Interstitial lung disease
Neutropenia (an abnormally low number of neutrophils)
Presyncope

What are the common drug interactions of Emend and Tecentriq, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Arthritis (form of joint disorder that involves inflammation of one or more joints)
Neuropathy peripheral (surface nerve damage)

50-59:

Ascites (accumulation of fluid in the abdominal cavity)
Gastric hypomotility (less movement of stomach)
Neutropenia (an abnormally low number of neutrophils)
Pyrexia (fever)
Rash
Lung disorder (lung disease)
Platelet count decreased
Small cell lung cancer (small cell cancer tumour of lung)
Drug eruption (adverse drug reaction of the skin)
Gastroenteritis (inflammation of stomach and intestine)

60+:

Febrile neutropenia (fever with reduced white blood cells)
Neuropathy peripheral (surface nerve damage)
Duodenitis haemorrhagic (inflammation of the duodenum with bleeding disorder)
Epistaxis (bleed from the nose)
Interstitial lung disease
Presyncope
Skin disorder (skin disease)
Small cell lung cancer (small cell cancer tumour of lung)
Swelling face
Aplastic anaemia (blood disorder in which the body's bone marrow doesn't make enough new blood cells)

What are the existing conditions these people have? *

Lung Cancer - Small Cell (lung cancer): 14 people, 35.90%
Lung Cancer - Non-Small Cell (lung cancer): 11 people, 28.21%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 7 people, 17.95%
Pain: 4 people, 10.26%
Lung Neoplasm Malignant (cancer tumour of lung): 3 people, 7.69%
Fever: 3 people, 7.69%
Myelosuppression (a decrease in the production of blood cells): 2 people, 5.13%
Hiccups (an involuntary spasm of the diaphragm and respiratory organs, with a sudden closure of the glottis and a sound like a cough): 2 people, 5.13%
Cough: 2 people, 5.13%
Breast Cancer: 2 people, 5.13%

* Approximation only. Some reports may have incomplete information.

Do you take Emend and Tecentriq?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously